Elaine Hurt
Executive Director & Head, Tumour Targeted Delivery Bioscience, Oncology R&D AstraZeneca
Dr. Elaine Hurt, Executive Director of Tumor Targeted Delivery at AstraZeneca, leads target identification and preclinical development for innovative antibody-drug conjugates and radioconjugates. She earned her PhD at the University of Minnesota, focusing on estrogen receptor signaling, and completed postdoctoral work at the National Cancer Institute, advancing lymphoma and myeloma research. Since joining AstraZeneca in 2010, Dr. Hurt has introduced several novel drug targets, now in clinical trials. With 65+ publications and 12,000 citations, she is also an Adjunct Associate Professor at the University of Maryland, co-inventor on multiple patents, and frequent international conference speaker.
Seminars
- Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen therapeutic index and bring patient benefit
- Incorporating in silico and AI tools to enhance the ADC discovery toolbox and deliver next-generation ADC engineering and design
- Highlighting future priorities for next-generation ADC development, including exploring the potential of radio conjugates
- Understanding the 2026 ADC landscape and how the bar has been raised to develop and deliver differentiated ADCs with meaningful patient impact
- Assessing the need for novel ADC chemistry innovation: What is showing the most promise across novel payloads and conjugation technologies?
- Discussing the potential of novel ADC biology approaches across bispecific targeting and antibody engineering to unlock next generation ADC therapies
- Highlighting methods to best pursue ADC clinical differentiation across patient selections methods, combination strategies, and well executed clinical design
